Third Harmonic Bio, Inc. financial data

Location
San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q1 2025 - 08 May 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 4401% % -21%
Debt-to-equity 3.2% % 5.6%
Return On Equity -19% % -76%
Return On Assets -19% % -76%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 45,103,899 shares 11%
Common Stock, Shares, Outstanding 44,956,238 shares 12%
Entity Public Float $298,500,000 USD 247%
Common Stock, Value, Issued $5,000 USD 25%
Weighted Average Number of Shares Outstanding, Basic 44,917,032 shares 12%
Weighted Average Number of Shares Outstanding, Diluted 44,917,032 shares 12%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $40,919,000 USD 74%
General and Administrative Expense $25,379,000 USD 28%
Operating Income (Loss) $66,298,000 USD -53%
Nonoperating Income (Expense) $12,851,000 USD -5.9%
Net Income (Loss) Attributable to Parent $53,447,000 USD -81%
Earnings Per Share, Basic 1 USD/shares 65%
Earnings Per Share, Diluted 1 USD/shares 65%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $271,611,000 USD 3.3%
Assets, Current $275,997,000 USD 3.9%
Deferred Income Tax Assets, Net $38,203,000 USD 50%
Property, Plant and Equipment, Net $117,000 USD -25%
Operating Lease, Right-of-Use Asset $2,845,000 USD -21%
Other Assets, Noncurrent $414,000 USD -43%
Assets $279,836,000 USD 3.4%
Accounts Payable, Current $2,683,000 USD 184%
Liabilities, Current $5,102,000 USD 27%
Operating Lease, Liability, Noncurrent $2,113,000 USD -30%
Liabilities $7,215,000 USD 2.8%
Retained Earnings (Accumulated Deficit) $175,523,000 USD -44%
Stockholders' Equity Attributable to Parent $272,621,000 USD 3.5%
Liabilities and Equity $279,836,000 USD 3.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $13,477,000 USD -114%
Net Cash Provided by (Used in) Financing Activities $35,000 USD -29%
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 44,956,238 shares 12%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $13,442,000 USD -115%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $285,516,000 USD 5.9%
Deferred Tax Assets, Valuation Allowance $38,203,000 USD 50%
Deferred Tax Assets, Gross $39,124,000 USD 47%
Operating Lease, Liability $3,002,000 USD -20%
Depreciation $13,000 USD 8.3%
Payments to Acquire Property, Plant, and Equipment $0 USD
Lessee, Operating Lease, Liability, to be Paid $3,480,000 USD -24%
Property, Plant and Equipment, Gross $214,000 USD 4.9%
Operating Lease, Liability, Current $889,000 USD 15%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,207,000 USD 2.6%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,176,000 USD 2.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $478,000 USD -42%
Lessee, Operating Lease, Liability, to be Paid, Year Three $238,000 USD -80%
Deferred Tax Assets, Operating Loss Carryforwards $15,080,000 USD 26%
Preferred Stock, Shares Issued 0 shares
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $238,000 USD -80%
Operating Lease, Payments $1,116,000 USD 35%
Additional Paid in Capital $448,139,000 USD 16%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $12,133,000 USD 33%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%